Sign up
Pharma Capital

Acasti Pharma granted allowance for patents in 3 more countries for drug candidate Capre

Acasti Pharma (NASDAQ: ACST-CVE:ACST) Co-Founder and Chief Operating Officer Pierre Lemieux joined Steve Darling from Proactive Investors Vancouver to bring news Acasti received 3 new patents for their flagship drug candidate CaPre.

Lemieux talks about what this means for the company going forward and where in the pipeline CaPre is and what trials will happen this year.


View full ACST profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.